BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
90.89
-1.33 (-1.44%)
At close: Jun 18, 2026, 4:00 PM EDT
90.85
-0.04 (-0.04%)
After-hours: Jun 18, 2026, 7:50 PM EDT
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
$414,296
Profits / Employee
-$184,935
Market Cap
22.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
BNTX News
- 3 days ago - Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO - Reuters
- 19 days ago - BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial - TheFly
- 21 days ago - Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewsWire
- 24 days ago - This Biotech's Cancer Portfolio Could End Its Rough Patch - Barrons
- 24 days ago - BioNTech upgraded to Buy from Neutral at UBS - TheFly
- 4 weeks ago - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Bernstein starts BioNTech at Market Perform, sees high registration risk - TheFly
- 4 weeks ago - BioNTech initiated with a Market Perform at Bernstein - TheFly